Company profile

FimmCyte AG

One in 10 women suffer from Endometriosis: a painful, chronic, infertility causing and recurrent disease. Endometriosis has a physical health burden comparable to cancer, yet only one new treatment was approved for it in the past decade. An unacceptable state given the inadequacy of current treatments which are only palliative, with countless side effects. Endometriosis' burden reverberates through the healthcare system, economy, and society with millions of women suffering and billions of direct and indirect costs. To address this unmet medical need, we engineered a first-in-class treatment that has shown efficacy in eliminating endometriosis tissue in the lab and animal models which we aim to bring to the clinic in the next few years and give women back control of their body.

Highlights

Winner Venture KickWinner Venture Kick

More news about FimmCyte AG

29.02.2024 10:40

FimmCyte obtains CHF 1 million from the UZH Life Sciences Fund

Please login or
register to use the
awards follow feature
06.10.2023 11:22

Four startups to accelerate their therapeutics with BaseLaunch

Please login or
register to use the
awards follow feature
21.07.2022 12:00

Ten Biotech startups brace for Boston

Please login or
register to use the
awards follow feature
13.07.2022 15:00

FimmCyte obtains CHF 150’000 to tackle Endometriosis

Please login or
register to use the
awards follow feature
31.03.2022 15:15

A second cohort joins Tech4Eva accelerator

Please login or
register to use the
awards follow feature
24.02.2022 13:50

New projects to fast-track progress with Innobooster

Please login or
register to use the
awards follow feature
FimmCyte AG

Founded
2022

Kanton
BS

Homepage

rss